Compare Cassava Sciences Inc (FLNA) vs General Dynamics Corporation (GD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs General Dynamics Corporation — how do they compare? Cassava Sciences Inc trades at $0.82 (market cap $39.40M), while General Dynamics Corporation trades at $331.32 (market cap $88.37B). The key difference: General Dynamics Corporation is far larger — about 2242.9× Cassava Sciences Inc's market cap, and General Dynamics Corporation pays a 1.95% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cassava Sciences Inc for 37 Days and General Dynamics Corporation for 85 Days on average.
| FLNA | GD | |
|---|---|---|
Market Cap | $39.40M | $88.37B |
Volume | 759,018 | 1,251,409 |
Sector | Health | Industrials |
52-Week High | $4.64 | $395.97 |
52-Week Low | $0.68 | $312.53 |
Typical Hold Time | 37 Days | 85 Days |
Enterprise Value | -$43.28M | $93.52B |
Dividend Yield | — | 1.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.8136, down 7.01% today, with a bearish technical signal from moving averages. The company shows negative profitability with ROE at -55.79% and ROA at -35.34%, though it has beaten EPS estimates for three consecutive quarters. Recent FDA approval to lift the clinical hold on simufilam for epilepsy research provides a positive catalyst, with patient screening expected by Q1 2027.
Despite operational losses and negative cash flow, analyst consensus is bullish with 8 buy ratings versus 4 hold. The key investment opportunity lies in the clinical progress of simufilam, while risks include sustained cash burn and reliance on successful drug development outcomes in a competitive biotech landscape.
General Dynamics (GD) trades at $329.90, down 0.43% with bearish technical signals despite strong fundamentals. The defense contractor shows consistent revenue growth to $52.55B in 2025 and has beaten earnings estimates for three consecutive quarters. Analyst consensus remains strongly bullish with a $420.57 price target, while technical indicators show oversold conditions with RSI at 11.03.
GD offers solid value with reasonable valuation multiples and strong defense contract visibility, though near-term technical weakness and dependence on government spending create volatility. The stock's 27% upside to consensus target and consistent dividend payments provide attractive total return potential for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About General Dynamics Corporation
General Dynamics is a defense contractor and business jet manufacturer. The firm's segments include aerospace, combat systems, marine, and technologies. The company's aerospace segment creates Gulfstream business jets. Combat system produces land-based combat vehicles, such as the M1 Abrams tank. The marine subsegment creates nuclear-powered submarines, among other things. The technologies segment contains two main units, an IT business that primarily serves the government market and a mission systems business that focuses on products that provide command, control, computers, intelligence, surveillance, and reconnaissance capabilities to the military.
Read more on GD →
